Supriya Lifescience Ltd
Supriya Lifescience Ltd (SUPRIYA) last reported results for the quarter ended Jun 2026, with sales of ₹190 crore and net profit of ₹24 crore. The stock last traded at ₹909, a market capitalisation of ₹7,318 crore, on a P/E of 36.8. Over the past 52 weeks the stock has ranged between ₹546 and ₹1,086. Figures are as of 6 Oct 2026 and are not real time.
Supriya Lifescience Ltd share price and key metrics
- Current price
- ₹909
- Market cap
- ₹7,318 cr
- Stock P/E
- 36.8
- Book value
- ₹149
- ROE
- 19.1%
- ROCE
- 25.2%
- Dividend yield
- 0.11%
- 52w high / low
- 1086/546
Metrics as of 6 Oct 2026. Not real time.
Track Supriya Lifescience Ltd
Cruxal reads every Supriya Lifescience Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Supriya Lifescience Ltd growth and returns
- 10 Years
- %
- 5 Years
- 16%
- 3 Years
- 22%
- TTM
- 28%
- 10 Years
- %
- 5 Years
- 11%
- 3 Years
- 32%
- TTM
- 12%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- 49%
- 1 Year
- 24%
- 10 Years
- 23%
- 5 Years
- 20%
- 3 Years
- 19%
- Last Year
- 19%
Supriya Lifescience Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹190 cr, up 31.0% from ₹145 cr a year earlier. Net profit was ₹24 cr, down 31.4% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 166 | 186 | 184 | 145 | 200 | 206 | 277 | 190 |
| Expenses | 101 | 120 | 117 | 93 | 127 | 134 | 179 | 142 |
| Operating profit | 65 | 66 | 68 | 52 | 73 | 72 | 98 | 47 |
| OPM % | 39% | 36% | 37% | 36% | 36% | 35% | 35% | 25% |
| Other income | 3 | 2 | 3 | 3 | 3 | 2 | 3 | 3 |
| Interest | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 |
| Depreciation | 5 | 5 | 6 | 6 | 7 | 7 | 8 | 9 |
| Profit before tax | 62 | 63 | 64 | 47 | 68 | 67 | 92 | 41 |
| Tax % | 26% | 25% | 21% | 27% | 26% | 26% | 19% | 41% |
| Net profit | 46 | 47 | 50 | 35 | 50 | 50 | 74 | 24 |
| EPS (₹) | 5.73 | 5.81 | 6.26 | 4.32 | 6.27 | 6.17 | 9.22 | 2.99 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Supriya Lifescience Ltd annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 184 | 213 | 278 | 312 | 391 | 530 | 461 | 570 | 696 | 828 | 873 |
| Operating profit | 17 | 22 | 65 | 98 | 173 | 214 | 129 | 176 | 261 | 295 | 290 |
| OPM % | 9% | 10% | 23% | 32% | 44% | 40% | 28% | 31% | 37% | 36% | 33% |
| Net profit | 6 | 9 | 39 | 73 | 124 | 152 | 90 | 119 | 188 | 209 | 198 |
| EPS (₹) | 3.87 | 5.96 | 26.93 | 50.11 | 16.89 | 18.86 | 11.17 | 14.80 | 23.35 | 25.98 | 24.65 |
TTM is the trailing twelve months to the most recent quarter.
Supriya Lifescience Ltd balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 15 | 15 | 15 | 15 | 15 | 16 | 16 | 16 | 16 | 16 |
| Reserves | 31 | 40 | 79 | 134 | 254 | 600 | 683 | 799 | 981 | 1,182 |
| Borrowings | 140 | 130 | 90 | 82 | 72 | 27 | 22 | 5 | 5 | 5 |
| Other liabilities | 55 | 60 | 69 | 105 | 105 | 92 | 98 | 101 | 115 | 154 |
| Total liabilities | 241 | 245 | 253 | 336 | 445 | 735 | 820 | 921 | 1,117 | 1,357 |
| Fixed assets | 89 | 91 | 85 | 99 | 100 | 190 | 262 | 310 | 453 | 689 |
| CWIP | 36 | 34 | 35 | 40 | 79 | 43 | 68 | 149 | 148 | 36 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 25 | 64 | 63 | 99 |
| Other assets | 117 | 120 | 133 | 197 | 267 | 502 | 466 | 399 | 453 | 534 |
| Total assets | 241 | 245 | 253 | 336 | 445 | 735 | 820 | 921 | 1,117 | 1,357 |
As reported by the company. Total assets equal total liabilities by construction.
Supriya Lifescience Ltd cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 27 | 28 | 49 | 117 | 76 | 49 | 64 | 113 | 165 | 186 |
| Cash from investing | -27 | -5 | 5 | -25 | -47 | -60 | -124 | -174 | -152 | -176 |
| Cash from financing | -2 | -20 | -50 | -29 | -15 | 150 | -10 | -22 | -8 | -10 |
| Net cash flow | -2 | 3 | 4 | 62 | 15 | 139 | -70 | -83 | 4 | -0 |
| Free cash flow | -0 | 23 | 54 | 92 | 29 | -11 | -44 | -32 | 2 | 34 |
| CFO / operating profit | 158% | 141% | 97% | 146% | 61% | 51% | 73% | 86% | 86% | 84% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Supriya Lifescience Ltd operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | — | 14% | 37% | 50% | 60% | 43% | 19% | 22% | 27% | 25% |
| Debtor days | 99 | 92 | 79 | 60 | 69 | 79 | 67 | 71 | 70 | 97 |
| Inventory days | 113 | 85 | 77 | 130 | 206 | 172 | 234 | 140 | 205 | 229 |
| Days payable | 121 | 112 | 110 | 130 | 145 | 91 | 130 | 98 | 129 | 159 |
| Cash conversion cycle | 91 | 64 | 45 | 61 | 130 | 160 | 171 | 114 | 146 | 167 |
| Working capital days | -69 | -50 | -5 | -40 | 28 | 117 | 168 | 157 | 144 | 147 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Supriya Lifescience Ltd shareholding pattern
Promoters held 68.30% at Jun 2026, broadly unchanged since Jun 2025. FIIs 6.18% and DIIs 5.30%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 68.30% | 68.30% | 68.30% | 68.30% | 68.30% | 68.30% | 68.30% | 68.30% |
| FIIs | 6.03% | 6.52% | 7.19% | 6.78% | 5.46% | 5.19% | 5.16% | 6.18% |
| DIIs | 5.45% | 4.93% | 4.26% | 4.86% | 5.22% | 5.00% | 5.70% | 5.30% |
| Public | 20.22% | 20.25% | 20.25% | 20.08% | 21.02% | 21.49% | 20.83% | 20.21% |
| No. of shareholders | 85,328 | 89,394 | 91,051 | 91,928 | 87,912 | 85,099 | 81,161 | 82,082 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Supriya Lifescience Ltd corporate filings
- SEBI Regulation 30 Filing by Supriya Lifescience Ltd (543434) Enclosed for RecordCompany Updatelow impact
Cruxal's analysis: Supriya Lifescience Ltd has submitted a regulatory disclosure under SEBI (LODR)…
Read the full analysis - The Intimation of closure of window for trading in securities of the Company by Designated Persons and their Immediate relatives for the quarter and half year ending on September 30, 2026, ....Insider Trading / SASTlow impact
- Supriya Lifescience Limited concludes 18th AGM; shareholders approve final dividend of INR 1.00 per shareAGM/EGMlow impact
Cruxal's analysis: Supriya Lifescience Limited has successfully concluded its 18th Annual General Meeting…
Read the full analysis - Supriya Lifescience Ltd files routine regulatory disclosure under SEBI LODRCompany Updatelow impact
Cruxal's analysis: Supriya Lifescience Ltd has submitted a routine announcement under Regulation 30 of the…
Read the full analysis - Supriya Lifescience Ltd schedules analyst/investor meetingCompany Updatelow impact
Cruxal's analysis: Supriya Lifescience has issued a routine intimation regarding an upcoming…
Read the full analysis - Supriya Lifescience Ltd schedules investor/analyst meetingCompany Updatelow impact
Cruxal's analysis: Supriya Lifescience Ltd has issued an intimation regarding an upcoming investor/analyst…
Read the full analysis - Supriya Lifescience Ltd dispatches communication to shareholders with unregistered email IDsCompany Updatelow impact
Cruxal's analysis: Supriya Lifescience Ltd has issued a formal intimation regarding the dispatch of letters…
Read the full analysis - Supriya Lifescience Ltd files routine disclosure under Regulation 30Company Updatelow impact
Cruxal's analysis: Supriya Lifescience Ltd has submitted a disclosure under Regulation 30 of the SEBI (LODR)…
Read the full analysis - Supriya Lifescience Limited Announces 18th Annual General Meeting Scheduled for September 24, 2026Company Updatelow impact
Cruxal's analysis: Supriya Lifescience Limited has issued a formal notice for its 18th Annual General…
Read the full analysis - Supriya Lifescience Ltd files Business Responsibility and Sustainability Report (BRSR) for FY 2025-26Otherslow impact
Cruxal's analysis: Supriya Lifescience Ltd has submitted its Business Responsibility and Sustainability…
Read the full analysis - Supriya Lifescience Limited Announces 18th Annual General Meeting and Final Dividend of INR 1.00 per shareAGM/EGMlow impact
Cruxal's analysis: Supriya Lifescience Limited has issued the notice for its 18th Annual General Meeting…
Read the full analysis - Supriya Lifescience Ltd files Annual Report for FY 2025-26Otherslow impact
Cruxal's analysis: Supriya Lifescience Ltd has submitted its Annual Report for the financial year 2025-26 in…
Read the full analysis - Supriya Lifescience Ltd publishes routine newspaper notice regarding corporate disclosuresCompany Updatelow impact
Cruxal's analysis: Supriya Lifescience Ltd has filed a copy of a newspaper publication as part of its…
Read the full analysis - Supriya Lifescience Limited announces September 4, 2026 as Record Date for final dividend of INR 1.00 per shareCorp. Actionlow impact
Cruxal's analysis: Supriya Lifescience Limited has formally notified the exchanges that Friday, September 4…
Read the full analysis - Supriya Lifescience Limited announces successful re-appointment of Mr. Balasaheb Sawant as Whole Time DirectorAGM/EGMlow impact
Cruxal's analysis: Supriya Lifescience Limited has confirmed the re-appointment of Mr. Balasaheb Sawant as…
Read the full analysis - Supriya Lifescience Q1 FY27 Earnings Call Transcript: Temporary Margin Headwinds Addressed; Growth Guidance MaintainedCompany Updatemedium impact
Cruxal's analysis: Supriya Lifescience reported Q1 FY27 revenue of 190 crore, a 31% YoY growth, despite…
Read the full analysis - Supriya Lifescience Limited releases audio recording of Q1 FY2027 earnings callCompany Updatelow impact
Cruxal's analysis: Supriya Lifescience Limited has formally uploaded the audio recording of its earnings…
Read the full analysis - Supriya Lifescience Q1 FY27 Results: Revenue and Profit Decline YoY, Signaling Operational HeadwindsCompany Updatehigh impact
Cruxal's analysis: Supriya Lifescience Limited reported Q1 FY27 standalone revenue of 189.75 crore…
Read the full analysis - Supriya Lifescience Q1 FY27 Results: 31% YoY Revenue Growth Offset by Margin ContractionCompany Updatehigh impact
Cruxal's analysis: Supriya Lifescience reported Q1 FY27 revenue of 189.75 crore, a 31% YoY increase, driven…
Read the full analysis - Supriya Lifescience Q1 FY27 Results: Revenue Grows 31% YoY, but Profitability Contracts SignificantlyCompany Updatehigh impact
Cruxal's analysis: Supriya Lifescience reported Q1 FY27 revenue of 189.75 crore, reflecting a 31% YoY…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.